CEO SUMMARY: Prices recently established for molecular diagnostic tests are so low that they put patient access in jeopardy, declared a new lab industry coalition in a statement delivered to members of Congress. Called the Coalition to Strengthen the Future of Molecular Diagnostics, the organization also told members of Congress that—not only are the prices […]
New MoPath Lab Coalition Takes its Case to Congress
Low rates for molecular diagnostic tests will jeopardize patient access, coalition says
- By Joseph Burns
- > From the Volume XX No. 8 - June 17, 2013 Issue
- Tags: acla, affordable care act, american clinical lab, american clinical laboratory, cap, clinical lab, clinical laboratories, Clinical Laboratory, cpt, cpt code, diagnostic testing, Diagnostic tests, ehi, hie, lab industry, laboratories, laboratory association, laboratory director, laboratory medicine, Medicare, Medicare Administrative Contractor, molecular diagnostic, molecular diagnostic test, molecular diagnostic testing, molecular diagnostic tests, molecular pathology, molecular testing, pathologists, pathology test, personalized medicine, private payer, the affordable care act, the laboratory
